STOCK TITAN

BESM Stock News

BESM OTC
Rhea-AI Summary

BioTissue (NASDAQ: BESM) completed the sale of its non-ocular Surgical and Wound Care business to BioStem (OTC: BSEM) on Jan 21, 2026. BioStem acquired exclusive rights to the Neox and Clarix product lines, and BioTissue's Surgical sales team and key support staff will join BioStem's commercial organization. BioTissue will continue manufacturing those products for BioStem while refocusing its commercial strategy on ocular therapies, including Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. Management frames the divestiture as a move to concentrate resources on eye care innovation and professional education.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none